1
|
Wu Y, Zhou Y, Guo Y, Ling Y, Li Y, Cai H. Protocol to prepare MUC1 glycopeptide vaccines and evaluate immunization effects in mice. STAR Protoc 2024; 5:103047. [PMID: 38691463 PMCID: PMC11070643 DOI: 10.1016/j.xpro.2024.103047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 03/07/2024] [Accepted: 04/15/2024] [Indexed: 05/03/2024] Open
Abstract
The tumor-associated mucin MUC1 is overexpressed in almost all types of epithelial tumor tissues, making it an attractive target antigen for cancer immunotherapy. Here we present a protocol to prepare MUC1 glycopeptide vaccines and to evaluate immunization effects in mice. We describe steps for synthesizing glycopeptide antigen and conjugating it with carrier protein to make vaccine candidates. We then detail procedures for mice immunization, antibody response evaluation, and cellular immune response. For complete details on the use and execution of this protocol, please refer to Cai et al.1,2.
Collapse
Affiliation(s)
- Ye Wu
- School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China
| | - Yang Zhou
- School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China
| | - Yajing Guo
- School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China
| | - Yi Ling
- School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China
| | - Yiliang Li
- The Eighth Affiliated Hospital Sun Yat-sen University, Shenzhen, Guangdong 518033, China.
| | - Hui Cai
- School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China.
| |
Collapse
|
2
|
Freitas R, Peixoto A, Ferreira E, Miranda A, Santos LL, Ferreira JA. Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines. Biotechnol Adv 2023; 65:108144. [PMID: 37028466 DOI: 10.1016/j.biotechadv.2023.108144] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 03/17/2023] [Accepted: 03/30/2023] [Indexed: 04/09/2023]
Abstract
Cancer remains a leading cause of death worldwide due to the lack of safer and more effective therapies. Cancer vaccines developed from neoantigens are an emerging strategy to promote protective and therapeutic anti-cancer immune responses. Advances in glycomics and glycoproteomics have unveiled several cancer-specific glycosignatures, holding tremendous potential to foster effective cancer glycovaccines. However, the immunosuppressive nature of tumours poses a major obstacle to vaccine-based immunotherapy. Chemical modification of tumour associated glycans, conjugation with immunogenic carriers and administration in combination with potent immune adjuvants constitute emerging strategies to address this bottleneck. Moreover, novel vaccine vehicles have been optimized to enhance immune responses against otherwise poorly immunogenic cancer epitopes. Nanovehicles have shown increased affinity for antigen presenting cells (APCs) in lymph nodes and tumours, while reducing treatment toxicity. Designs exploiting glycans recognized by APCs have further enhanced the delivery of antigenic payloads, improving glycovaccine's capacity to elicit innate and acquired immune responses. These solutions show potential to reduce tumour burden, while generating immunological memory. Building on this rationale, we provide a comprehensive overview on emerging cancer glycovaccines, emphasizing the potential of nanotechnology in this context. A roadmap towards clinical implementation is also delivered foreseeing advances in glycan-based immunomodulatory cancer medicine.
Collapse
Affiliation(s)
- Rui Freitas
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal; Abel Salazar Biomedical Sciences Institute - University of Porto (ICBAS), 4050-313 Porto, Portugal
| | - Andreia Peixoto
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal
| | - Eduardo Ferreira
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal
| | - Andreia Miranda
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Abel Salazar Biomedical Sciences Institute - University of Porto (ICBAS), 4050-313 Porto, Portugal
| | - Lúcio Lara Santos
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal; Abel Salazar Biomedical Sciences Institute - University of Porto (ICBAS), 4050-313 Porto, Portugal; Health School of University Fernando Pessoa, 4249-004 Porto, Portugal; GlycoMatters Biotech, 4500-162 Espinho, Portugal; Department of Surgical Oncology, Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal
| | - José Alexandre Ferreira
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute (IPO Porto), 4200-072 Porto, Portugal; Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal; GlycoMatters Biotech, 4500-162 Espinho, Portugal.
| |
Collapse
|
3
|
Su C, Zhong Y, Zhao G, Hou J, Zhang S, Wang B. RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. NPJ Vaccines 2022; 7:168. [PMID: 36535957 PMCID: PMC9762623 DOI: 10.1038/s41541-022-00591-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Accepted: 12/06/2022] [Indexed: 12/23/2022] Open
Abstract
Respiratory syncytial virus (RSV) infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection. Previously we demonstrated that an RSV vaccine, BARS13, consisting of recombinant G protein from E. coli plus cyclosporine A (CsA) as an immune-modulator, can protect animals from RSV challenge without inducing vaccine-enhanced disease (VED). To maximize the efficacy of such a vaccine, we introduced RSV pre-fusion F protein (pre-F) to form a new vaccine comprised of the pre-F and G proteins with the CsA. Two intramuscular immunizations with the vaccine induced a higher level of neutralizing antibodies against RSV and protected mice from RSV challenge without incurring VED. Interestingly, the addition of the pre-F to the vaccine facilitated anti-G antibody production and protection from RSV infection mainly via induction of antibodies against the central conserved domain (CCD) of the G protein which correlated with blocking the CX3C-CX3CR1 interaction. A 15 amino acid sequence (FP4) within the F2 region of pre-F served as a CD4+ Th epitope to facilitate the anti-G antibody response. Collectively, such a combination of the FP4 peptide with the G protein and CsA provides a novel strategy for developing a safe and maximally effective recombinant G protein-containing RSV vaccine.
Collapse
Affiliation(s)
- Caixia Su
- grid.8547.e0000 0001 0125 2443Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China ,grid.8547.e0000 0001 0125 2443Fudan-Advaccine Join-Lab for Vaccine Research, Fudan University, Shanghai, China
| | - Yiwei Zhong
- grid.8547.e0000 0001 0125 2443Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China ,grid.8547.e0000 0001 0125 2443Fudan-Advaccine Join-Lab for Vaccine Research, Fudan University, Shanghai, China ,Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China
| | - Gan Zhao
- Advaccine Biopharmaceutics (Suzhou) Co. LTD, Suzhou, Jiangsu Province China
| | - Jiawang Hou
- Advaccine Biopharmaceutics (Suzhou) Co. LTD, Suzhou, Jiangsu Province China
| | - Shuren Zhang
- grid.8547.e0000 0001 0125 2443Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China ,Present Address: Shenzhen Pregene Biopharma Company LTD, Shenzhen, China
| | - Bin Wang
- grid.8547.e0000 0001 0125 2443Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China ,grid.8547.e0000 0001 0125 2443Fudan-Advaccine Join-Lab for Vaccine Research, Fudan University, Shanghai, China ,Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China ,Advaccine Biopharmaceutics (Suzhou) Co. LTD, Suzhou, Jiangsu Province China ,grid.411405.50000 0004 1757 8861National Clinical Research Center for Geriatric Diseases, Huashan Hospital, Shanghai, China ,grid.411333.70000 0004 0407 2968Children’s Hospital of Fudan University, Shanghai, China
| |
Collapse
|
4
|
Shivatare SS, Shivatare VS, Wong CH. Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments. Chem Rev 2022; 122:15603-15671. [PMID: 36174107 PMCID: PMC9674437 DOI: 10.1021/acs.chemrev.1c01032] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Glycoconjugates are major constituents of mammalian cells that are formed via covalent conjugation of carbohydrates to other biomolecules like proteins and lipids and often expressed on the cell surfaces. Among the three major classes of glycoconjugates, proteoglycans and glycoproteins contain glycans linked to the protein backbone via amino acid residues such as Asn for N-linked glycans and Ser/Thr for O-linked glycans. In glycolipids, glycans are linked to a lipid component such as glycerol, polyisoprenyl pyrophosphate, fatty acid ester, or sphingolipid. Recently, glycoconjugates have become better structurally defined and biosynthetically understood, especially those associated with human diseases, and are accessible to new drug, diagnostic, and therapeutic developments. This review describes the status and new advances in the biological study and therapeutic applications of natural and synthetic glycoconjugates, including proteoglycans, glycoproteins, and glycolipids. The scope, limitations, and novel methodologies in the synthesis and clinical development of glycoconjugates including vaccines, glyco-remodeled antibodies, glycan-based adjuvants, glycan-specific receptor-mediated drug delivery platforms, etc., and their future prospectus are discussed.
Collapse
Affiliation(s)
- Sachin S Shivatare
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Vidya S Shivatare
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Chi-Huey Wong
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
- Genomics Research Center, Academia Sinica, Taipei 115, Taiwan
| |
Collapse
|
5
|
Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. Biomed Pharmacother 2020; 132:110888. [PMID: 33113416 DOI: 10.1016/j.biopha.2020.110888] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 10/05/2020] [Accepted: 10/12/2020] [Indexed: 12/30/2022] Open
Abstract
Mucin 1 (MUC1) is a transmembrane mucin glycoprotein expressed on the surface of almost all epithelial cells. Aberrantly glycosylated MUC1 is associated with cellular transformation from a normal to malignant phenotype in human cancers. Therefore, MUC1 is the major target for the design and development of cancer vaccines. MUC1-based cancer vaccines are a promising strategy for preventing cancer progression and metastasis. This review summarizes the most significant milestones achieved to date in the development of different MUC-1-based vaccine approaches in clinical trials. Further, it provides perspectives for future research that may promote clinical advances in infection-associated cancers.
Collapse
Affiliation(s)
- Tong Gao
- College of Medicine, Southwest Jiaotong University, Chengdu 610031, China
| | - Qianhong Cen
- College of Medicine, Southwest Jiaotong University, Chengdu 610031, China
| | - Han Lei
- College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
| |
Collapse
|
6
|
Marqvorsen MHS, Araman C, van Kasteren SI. Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System. Bioconjug Chem 2019; 30:2715-2726. [PMID: 31580646 PMCID: PMC6873266 DOI: 10.1021/acs.bioconjchem.9b00588] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 09/30/2019] [Indexed: 12/16/2022]
Abstract
Glycosylation plays a myriad of roles in the immune system: Certain glycans can interact with specific immune receptors to kickstart a pro-inflammatory response, whereas other glycans can do precisely the opposite and ameliorate the immune response. Specific glycans and glycoforms can themselves become the targets of the adaptive immune system, leading to potent antiglycan responses that can lead to the killing of altered self- or pathogenic species. This hydra-like set of roles glycans play is of particular importance in cancer immunity, where it influences the anticancer immune response, likely playing pivotal roles in tumor survival or clearance. The complexity of carbohydrate biology requires synthetic access to glycoproteins and glycopeptides that harbor homogeneous glycans allowing the probing of these systems with high precision. One particular complicating factor in this is that these synthetic structures are required to be as close to the native structures as possible, as non-native linkages can themselves elicit immune responses. In this Review, we discuss examples and current strategies for the synthesis of natively linked single glycoforms of peptides and proteins that have enabled researchers to gain new insights into glycoimmunology, with a particular focus on the application of these reagents in cancer immunology.
Collapse
Affiliation(s)
- Mikkel H. S. Marqvorsen
- Leiden
Institute of Chemistry, Institute for Chemical Immunology Gorlaeus
Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Can Araman
- Leiden
Institute of Chemistry, Institute for Chemical Immunology Gorlaeus
Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Sander I. van Kasteren
- Leiden
Institute of Chemistry, Institute for Chemical Immunology Gorlaeus
Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| |
Collapse
|
7
|
Pinzón Martín S, Seeberger PH, Varón Silva D. Mucins and Pathogenic Mucin-Like Molecules Are Immunomodulators During Infection and Targets for Diagnostics and Vaccines. Front Chem 2019; 7:710. [PMID: 31696111 PMCID: PMC6817596 DOI: 10.3389/fchem.2019.00710] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Accepted: 10/09/2019] [Indexed: 12/24/2022] Open
Abstract
Mucins and mucin-like molecules are highly O-glycosylated proteins present on the cell surface of mammals and other organisms. These glycoproteins are highly diverse in the apoprotein and glycan cores and play a central role in many biological processes and diseases. Mucins are the most abundant macromolecules in mucus and are responsible for its biochemical and biophysical properties. Mucin-like molecules cover various protozoan parasites, fungi and viruses. In humans, modifications in mucin glycosylation are associated with tumors in epithelial tissue. These modifications allow the distinction between normal and abnormal cell conditions and represent important targets for vaccine development against some cancers. Mucins and mucin-like molecules derived from pathogens are potential diagnostic markers and targets for therapeutic agents. In this review, we summarize the distribution, structure, role as immunomodulators, and the correlation of human mucins with diseases and perform a comparative analysis of mucins with mucin-like molecules present in human pathogens. Furthermore, we review the methods to produce pathogenic and human mucins using chemical synthesis and expression systems. Finally, we present applications of mucin-like molecules in diagnosis and prevention of relevant human diseases.
Collapse
Affiliation(s)
- Sandra Pinzón Martín
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.,Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany
| | - Peter H Seeberger
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.,Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany
| | - Daniel Varón Silva
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.,Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, Germany
| |
Collapse
|
8
|
Li M, Yu F, Yao C, Wang PG, Liu Y, Zhao W. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates. Org Biomol Chem 2019; 16:993-999. [PMID: 29345713 DOI: 10.1039/c7ob02976d] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Therapeutic vaccines have been regarded as a very promising treatment modality against cancer. Tumor-associated MUC1 is a promising antigen for the design of antitumor vaccines. However, body's immune tolerance and low immunogenicity of MUC1 glycopeptides limited their use as effective antigen epitopes of therapeutic vaccines. To solve this problem, we chose the immune dominant region of MUC1 VNTRs. We designed and synthesized its linear trivalent glycopeptide fragments and coupled the fragments with BSA. Immunological evaluation indicated that the antibodies induced by glycosylated MUC1 based vaccine 11 had a stronger binding than non-glycosylated 10. The novel constructed antigen epitopes have the potential to overcome the weak immunogenicity of natural MUC1 glycopeptides and deserve further research.
Collapse
Affiliation(s)
- Mingjing Li
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, P.R. China
| | | | | | | | | | | |
Collapse
|
9
|
Cadena AP, Cushman TR, Welsh JW. Glycosylation and Antitumor Immunity. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY 2019; 343:111-127. [DOI: 10.1016/bs.ircmb.2018.05.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
10
|
McDonald DM, Hanna CC, Ashhurst AS, Corcilius L, Byrne SN, Payne RJ. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization. ACS Chem Biol 2018; 13:3279-3285. [PMID: 30359529 DOI: 10.1021/acschembio.8b00675] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Access to lipopeptide-based vaccines for immunological studies remains a significant challenge owing to the amphipathic nature of the molecules, which makes them difficult to synthesize and purify to homogeneity. Here, we describe the application of a new peptide ligation technology, the diselenide-selenoester ligation (DSL), to access self-adjuvanting glycolipopeptide vaccines. We show that rapid ligation of glyco- and lipopeptides is possible via DSL in mixed organic solvent-aqueous buffer and, when coupled with deselenization chemistry, affords rapid and efficient access to a vaccine candidate possessing a MUC1 glycopeptide epitope and the lipopeptide adjuvant Pam2Cys. This construct was shown to elicit MUC1-specific antibody and cytotoxic T lymphocyte responses in the absence of any other injected lipids or adjuvants. The inclusion of the helper T cell epitope PADRE both boosted the antibody response and resulted in elevated cytokine production.
Collapse
Affiliation(s)
- David M. McDonald
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
- Infectious Diseases and Immunology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Cameron C. Hanna
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Anneliese S. Ashhurst
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
- Infectious Diseases and Immunology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Leo Corcilius
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Scott N. Byrne
- Infectious Diseases and Immunology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Richard J. Payne
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
11
|
Wu X, Yin Z, McKay C, Pett C, Yu J, Schorlemer M, Gohl T, Sungsuwan S, Ramadan S, Baniel C, Allmon A, Das R, Westerlind U, Finn MG, Huang X. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice. J Am Chem Soc 2018; 140:16596-16609. [PMID: 30398345 DOI: 10.1021/jacs.8b08473] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Human mucin-1 (MUC1) is a highly attractive antigen for the development of anticancer vaccines. However, in human clinical trials of multiple MUC1 based vaccines, despite the generation of anti-MUC1 antibodies, the antibodies often failed to exhibit much binding to tumor presumably due to the challenges in inducing protective immune responses in the immunotolerant environment. To design effective MUC1 based vaccines functioning in immunotolerant hosts, vaccine constructs were first synthesized by covalently linking the powerful bacteriophage Qβ carrier with MUC1 glycopeptides containing 20-22 amino acid residues covering one full length of the tandem repeat region of MUC1. However, IgG antibodies elicited by these first generation constructs in tolerant human MUC1 transgenic (Tg) mice did not bind tumor cells strongly. To overcome this, a peptide array has been synthesized. By profiling binding selectivities of antibodies, the long MUC1 glycopeptide was found to contain immunodominant but nonprotective epitopes. Critical insights were obtained into the identity of the key protective epitope. Redesign of the vaccine focusing on the protective epitope led to a new Qβ-MUC1 construct, which was capable of inducing higher levels of anti-MUC1 IgG antibodies in MUC1.Tg mice to react strongly with and kill a wide range of tumor cells compared to the construct containing the gold standard protein carrier, i.e., keyhole limpet hemocyanin. Vaccination with this new Qβ-MUC1 conjugate led to significant protection of MUC1.Tg mice in both metastatic and solid tumor models. The antibodies exhibited remarkable selectivities toward human breast cancer tissues, suggesting its high translational potential.
Collapse
Affiliation(s)
| | | | - Craig McKay
- School of Chemistry & Biochemistry and School of Biological Sciences , Georgia Institute of Technology , Atlanta , Georgia 30332 , United States
| | - Christian Pett
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V. , 44227 Dortmund , Germany.,Department of Chemistry , Umeå University , 901 87 Umeå , Sweden
| | - Jin Yu
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V. , 44227 Dortmund , Germany
| | - Manuel Schorlemer
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V. , 44227 Dortmund , Germany
| | - Trevor Gohl
- Department of Physiology , Michigan State University , East Lansing , Michigan 48824 , United States
| | | | - Sherif Ramadan
- Chemistry Department, Faculty of Science , Benha University , Benha , Qaliobiya 13518 , Egypt
| | | | | | - Rupali Das
- Department of Physiology , Michigan State University , East Lansing , Michigan 48824 , United States
| | - Ulrika Westerlind
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V. , 44227 Dortmund , Germany.,Department of Chemistry , Umeå University , 901 87 Umeå , Sweden
| | - M G Finn
- School of Chemistry & Biochemistry and School of Biological Sciences , Georgia Institute of Technology , Atlanta , Georgia 30332 , United States
| | | |
Collapse
|
12
|
Szekely T, Roy O, Dériaud E, Job A, Lo-Man R, Leclerc C, Taillefumier C. Design, Synthesis, and Immunological Evaluation of a Multicomponent Construct Based on a Glycotripeptoid Core Comprising B and T Cell Epitopes and a Toll-like Receptor 7 Agonist That Elicits Potent Immune Responses. J Med Chem 2018; 61:9568-9582. [PMID: 30351939 DOI: 10.1021/acs.jmedchem.8b00960] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
We present here for the first time the synthesis and immunological evaluation of a fully synthetic three-component anticancer vaccine candidate that consists of a β-glycotripeptoid core mimicking a cluster of Tn at the surface of tumor cells (B epitope), conjugated to the OVA 323-339 peptide (T-cell epitope) and a Toll-like receptor 7 (TLR7) agonist for potent adjuvanticity. The immunological evaluation of this construct and of precursor components demonstrated the synergistic activity of the components within the conjugate to stimulate innate and adaptive immune cells (DCs, T-helper, and B-cells). Surprisingly, immunization of mice with the tricomponent GalNAc-based construct elicited a low level of anti-Tn IgG but elicited a very high level of antibodies that recognize the TLR7 agonist. This finding could represent a potential vaccine therapeutic approach for the treatment of some autoimmune diseases such as lupus.
Collapse
Affiliation(s)
- Thomas Szekely
- Université Clermont Auvergne, CNRS, SIGMA Clermont, ICCF , F-63000 Clermont-Ferrand , France
| | - Olivier Roy
- Université Clermont Auvergne, CNRS, SIGMA Clermont, ICCF , F-63000 Clermont-Ferrand , France
| | - Edith Dériaud
- Unité Régulation Immunitaire et Vaccinologie, Equipe Labellisée Ligue Contre le Cancer , Institut Pasteur , 75015 Paris , France.,INSERM U1041 , 75724 Paris Cedex 15, France
| | - Aurélie Job
- Université Clermont Auvergne, CNRS, SIGMA Clermont, ICCF , F-63000 Clermont-Ferrand , France
| | - Richard Lo-Man
- Unité Régulation Immunitaire et Vaccinologie, Equipe Labellisée Ligue Contre le Cancer , Institut Pasteur , 75015 Paris , France.,INSERM U1041 , 75724 Paris Cedex 15, France
| | - Claude Leclerc
- Unité Régulation Immunitaire et Vaccinologie, Equipe Labellisée Ligue Contre le Cancer , Institut Pasteur , 75015 Paris , France.,INSERM U1041 , 75724 Paris Cedex 15, France
| | - Claude Taillefumier
- Université Clermont Auvergne, CNRS, SIGMA Clermont, ICCF , F-63000 Clermont-Ferrand , France
| |
Collapse
|
13
|
Affiliation(s)
- Xuedan He
- University at Buffalo; State University of New York; Buffalo NY 14260 USA
| | - Scott I. Abrams
- Roswell Park Comprehensive Cancer Center; Department of Immunology; Buffalo NY 14263 USA
| | - Jonathan F. Lovell
- University at Buffalo; State University of New York; Buffalo NY 14260 USA
| |
Collapse
|
14
|
Straßburger D, Glaffig M, Stergiou N, Bialas S, Besenius P, Schmitt E, Kunz H. Synthetic MUC1 Antitumor Vaccine with Incorporated 2,3-Sialyl-T Carbohydrate Antigen Inducing Strong Immune Responses with Isotype Specificity. Chembiochem 2018; 19:1142-1146. [PMID: 29633523 DOI: 10.1002/cbic.201800148] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Indexed: 11/10/2022]
Abstract
The endothelial glycoprotein MUC1 is known to underlie alterations in cancer by means of aberrant glycosylation accompanied by changes in morphology. The heavily shortened glycans induce a collapse of the peptide backbone and enable accessibility of the latter to immune cells, rendering it a tumor-associated antigen. Synthetic vaccines based on MUC1 tandem repeat motifs, comprising tumor-associated 2,3-sialyl-T antigen, conjugated to the immunostimulating tetanus toxoid, are reported herein. Immunization with these vaccines in a simple water/oil emulsion produced a strong immune response in mice to which stimulation with complete Freund's adjuvant (CFA) was not superior. In both cases, high levels of IgG1 and IgG2a/b were induced in C57BL/6 mice. Additional glycosylation in the immunodominant PDTRP domain led to improved binding of the induced antisera to MCF-7 breast tumor cells, compared with that of the monoglycosylated peptide vaccine.
Collapse
Affiliation(s)
- David Straßburger
- Institut für Organische Chemie, Johannes Gutenberg-Universität Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Markus Glaffig
- Institut für Organische Chemie, Johannes Gutenberg-Universität Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Natascha Stergiou
- Institut für Immunologie, Johannes Gutenberg-Universität Mainz, Obere Zahlbacher Strasse 67, 55101, Mainz, Germany
| | - Sabrina Bialas
- Institut für Organische Chemie, Johannes Gutenberg-Universität Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Pol Besenius
- Institut für Organische Chemie, Johannes Gutenberg-Universität Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Edgar Schmitt
- Institut für Immunologie, Johannes Gutenberg-Universität Mainz, Obere Zahlbacher Strasse 67, 55101, Mainz, Germany
| | - Horst Kunz
- Institut für Organische Chemie, Johannes Gutenberg-Universität Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| |
Collapse
|
15
|
Yamazaki Y, Nambu Y, Ohmae M, Sugai M, Kimura S. Immune responses against Lewis Y tumor-associated carbohydrate antigen displayed densely on self-assembling nanocarriers. Org Biomol Chem 2018; 16:8095-8105. [DOI: 10.1039/c8ob01955j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Immune responses against Lewis Y (LY) displayed at varying densities on the nanocarriers were studied.
Collapse
Affiliation(s)
- Yuji Yamazaki
- Department of Material Chemistry
- Graduate School of Engineering
- Kyoto University
- Kyoto 615-8510
- Japan
| | - Yukiko Nambu
- Division of Molecular Genetics
- Department of Biochemistry and Bioinformative Sciences
- School of Medicine
- University of Fukui
- Fukui 910-1193
| | - Masashi Ohmae
- Department of Material Chemistry
- Graduate School of Engineering
- Kyoto University
- Kyoto 615-8510
- Japan
| | - Manabu Sugai
- Division of Molecular Genetics
- Department of Biochemistry and Bioinformative Sciences
- School of Medicine
- University of Fukui
- Fukui 910-1193
| | - Shunsaku Kimura
- Department of Material Chemistry
- Graduate School of Engineering
- Kyoto University
- Kyoto 615-8510
- Japan
| |
Collapse
|
16
|
Sun ZY, Chen PG, Liu YF, Shi L, Zhang BD, Wu JJ, Zhao YF, Chen YX, Li YM. Self-Assembled Nano-Immunostimulant for Synergistic Immune Activation. Chembiochem 2017; 18:1721-1729. [PMID: 28618135 DOI: 10.1002/cbic.201700246] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2017] [Indexed: 12/11/2022]
Abstract
Immunotherapy has become one of the most promising therapies for the treatment of diseases. Synthetic immunostimulants and nanomaterial immunostimulant systems are indispensable for the activation of the immune system in cancer immunotherapy. Herein, a strategy for preparing self-assembled nano-immunostimulants (SANIs) for synergistic immune activation is reported. Three immunostimulants self-assemble into nanoparticles through electrostatic interactions. SANIs showed strong synergistic immunostimulation in macrophages. SANIs could also induce a strong antitumor immune response to inhibit tumor growth in mice and act as an efficient adjuvant of antitumor vaccines. Therefore, SANIs may be generally applied in cancer immunotherapy. This novel SANI strategy provides a new way for the development of both immunostimulants and -suppressants.
Collapse
Affiliation(s)
- Zhan-Yi Sun
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Pu-Guang Chen
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yan-Fang Liu
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Lei Shi
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Bo-Dou Zhang
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Jun-Jun Wu
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yu-Fen Zhao
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yong-Xiang Chen
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | - Yan-Mei Li
- Key Lab of Bioorganic Phosphorus and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| |
Collapse
|
17
|
Leiria Campo V, Riul TB, Oliveira Bortot L, Martins-Teixeira MB, Fiori Marchiori M, Iaccarino E, Ruvo M, Dias-Baruffi M, Carvalho I. A Synthetic MUC1 Glycopeptide Bearing βGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells. Chembiochem 2017; 18:527-538. [PMID: 28068458 DOI: 10.1002/cbic.201600473] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 01/05/2017] [Indexed: 01/01/2023]
Abstract
This study presents the synthesis of the novel protected O-glycosylated amino acid derivatives 1 and 2, containing βGalNAc-SerOBn and βGalNAc-ThrOBn units, respectively, as mimetics of the natural Tn antigen (αGalNAc-Ser/Thr), along with the solid-phase assembly of the glycopeptides NHAcSer-Ala-Pro-Asp-Thr[αGalNAc]-Arg-Pro-Ala-Pro-Gly-BSA (3-BSA) and NHAcSer-Ala-Pro-Asp-Thr[βGalNAc]-Arg-Pro-Ala-Pro-Gly-BSA (4-BSA), bearing αGalNAc-Thr or βGalNAc-Thr units, respectively, as mimetics of MUC1 tumor mucin glycoproteins. According to ELISA tests, immunizations of mice with βGalNAc-glycopeptide 4-BSA induced higher sera titers (1:320 000) than immunizations with αGalNAc-glycopeptide 3-BSA (1:40 000). Likewise, flow cytometry assays showed higher capacity of the obtained anti-glycopeptide 4-BSA antibodies to recognize MCF-7 tumor cells. Cross-recognition between immunopurified anti-βGalNAc antibodies and αGalNAc-glycopeptide and vice versa was also verified. Lastly, molecular dynamics simulations and surface plasmon resonance (SPR) showed that βGalNAc-glycopeptide 4 can interact with a model antitumor monoclonal antibody (SM3). Taken together, these data highlight the improved immunogenicity of the unnatural glycopeptide 4-BSA, bearing βGalNAc-Thr as Tn antigen isomer.
Collapse
Affiliation(s)
- Vanessa Leiria Campo
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Thalita B Riul
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Leandro Oliveira Bortot
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Maristela B Martins-Teixeira
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Marcelo Fiori Marchiori
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Emanuela Iaccarino
- Istituto di Biostrutture e Bioimmagini, CNR, via Mezzocannone 16, 80134, Napoli, Italy.,Second University of Naples, via Vivaldi 43, 81100, Caserta, Italy
| | - Menotti Ruvo
- Istituto di Biostrutture e Bioimmagini, CNR, via Mezzocannone 16, 80134, Napoli, Italy
| | - Marcelo Dias-Baruffi
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| | - Ivone Carvalho
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP, 14040-903, Ribeirão Preto, São Paulo, Brazil
| |
Collapse
|
18
|
Pett C, Cai H, Liu J, Palitzsch B, Schorlemer M, Hartmann S, Stergiou N, Lu M, Kunz H, Schmitt E, Westerlind U. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures. Chemistry 2017; 23:3875-3884. [PMID: 27957769 DOI: 10.1002/chem.201603921] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Indexed: 01/08/2023]
Abstract
Glycoprotein research is pivotal for vaccine development and biomarker discovery. Many successful methodologies for reliably increasing the antigenicity toward tumor-associated glycopeptide structures have been reported. Deeper insights into the quality and specificity of the raised polyclonal, humoral reactions are often not addressed, despite the fact that an immunological memory, which produces antibodies with cross-reactivity to epitopes exposed on healthy cells, may cause autoimmune diseases. In the current work, three MUC1 antitumor vaccine candidates conjugated with different immune stimulants are evaluated immunologically. For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat. This is one of the most extensive glycopeptide libraries ever made through total synthesis. On tumor cells, the core 2 β-1,6-N-acetylglucosaminyltransferase-1 (C2GlcNAcT-1) is down-regulated, resulting in lower amounts of the branched core 2 structures, which favor formation of linear core 1 or core 3 structures, and in particular, truncated tumor-associated antigen structures. The core 2 structures are commonly found on healthy cells and the elucidation of antibody cross-reactivity to such epitopes may predict the tumor-selectivity and safety of synthetic vaccines. With the extended mucin core structures in hand, antibody cross-reactivity toward the branched core 2 glycopeptide epitopes is explored. It is observed that the induced antibodies recognize MUC1 peptides with very high glycosylation site specificity. The nature of the antibody response is characteristically different for antibodies directed to glycosylation sites in either the immune-dominant PDTR or the GSTA domain. All antibody sera show high reactivity to the tumor-associated saccharide structures on MUC1. Extensive glycosylation with branched core 2 structures, typically found on healthy cells, abolishes antibody recognition of the antisera and suggests that all vaccine conjugates preferentially induce a tumor-specific humoral immune response.
Collapse
Affiliation(s)
- Christian Pett
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| | - Hui Cai
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| | - Jia Liu
- Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
| | - Björn Palitzsch
- Institute of Organic Chemistry, Johannes Gutenberg, University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Manuel Schorlemer
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| | - Sebastian Hartmann
- Institute of Organic Chemistry, Johannes Gutenberg, University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Natascha Stergiou
- University Medical Center, Institute of Immunology, Johannes Gutenberg University of Mainz, Langenbeckstr. 1, Geb. 708, 55101, Mainz, Germany
| | - Mengji Lu
- Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
| | - Horst Kunz
- Institute of Organic Chemistry, Johannes Gutenberg, University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Edgar Schmitt
- University Medical Center, Institute of Immunology, Johannes Gutenberg University of Mainz, Langenbeckstr. 1, Geb. 708, 55101, Mainz, Germany
| | - Ulrika Westerlind
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| |
Collapse
|
19
|
Ho WL, Hsu WM, Huang MC, Kadomatsu K, Nakagawara A. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. J Hematol Oncol 2016; 9:100. [PMID: 27686492 PMCID: PMC5041531 DOI: 10.1186/s13045-016-0334-6] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 09/23/2016] [Indexed: 02/07/2023] Open
Abstract
Glycosylation is the most complex post-translational modification of proteins. Altered glycans on the tumor- and host-cell surface and in the tumor microenvironment have been identified to mediate critical events in cancer pathogenesis and progression. Tumor-associated glycan changes comprise increased branching of N-glycans, higher density of O-glycans, generation of truncated versions of normal counterparts, and generation of unusual forms of terminal structures arising from sialylation and fucosylation. The functional role of tumor-associated glycans (Tn, sTn, T, and sLea/x) is dependent on the interaction with lectins. Lectins are expressed on the surface of immune cells and endothelial cells or exist as extracellular matrix proteins and soluble adhesion molecules. Expression of tumor-associated glycans is involved in the dysregulation of glycogenes, which mainly comprise glycosyltransferases and glycosidases. Furthermore, genetic and epigenetic mechanisms on many glycogenes are associated with malignant transformation. With better understanding of all aspects of cancer-cell glycomics, many tumor-associated glycans have been utilized for diagnostic, prognostic, and therapeutic purposes. Glycan-based therapeutics has been applied to cancers from breast, lung, gastrointestinal system, melanomas, and lymphomas but rarely to neuroblastomas (NBs). The success of anti-disialoganglioside (GD2, a glycolipid antigen) antibodies sheds light on glycan-based therapies for NB and also suggests the possibility of protein glycosylation-based therapies for NB. This review summarizes our understanding of cancer glycobiology with a focus of how protein glycosylation and associated glycosyltransferases affect cellular behaviors and treatment outcome of various cancers, especially NB. Finally, we highlight potential applications of glycosylation in drug and cancer vaccine development for NB.
Collapse
Affiliation(s)
- Wan-Ling Ho
- School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 24205, Taiwan.,Department of Pediatrics, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.,Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
| | - Wen-Ming Hsu
- Department of Surgery, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100, Taiwan. .,Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan.
| | - Min-Chuan Huang
- Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan. .,Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, No. 1, Sec. 1, Jen-Ai Road, Taipei, 10051, Taiwan.
| | - Kenji Kadomatsu
- Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | |
Collapse
|
20
|
Cai H, Degliangeli F, Palitzsch B, Gerlitzki B, Kunz H, Schmitt E, Fiammengo R, Westerlind U. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein. Bioorg Med Chem 2016; 24:1132-5. [DOI: 10.1016/j.bmc.2016.01.044] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 01/18/2016] [Accepted: 01/21/2016] [Indexed: 01/23/2023]
|
21
|
Karmakar P, Lee K, Sarkar S, Wall KA, Sucheck SJ. Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses. Bioconjug Chem 2016; 27:110-20. [PMID: 26595674 PMCID: PMC4837471 DOI: 10.1021/acs.bioconjchem.5b00528] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Generation of a CD8(+) response to extracellular antigen requires processing of the antigen by antigen presenting cells (APC) and cross-presentation to CD8(+) T cell receptors via MHC class I molecules. Cross-presentation is facilitated by efficient antigen uptake followed by immune-complex-mediated maturation of the APCs. We hypothesize that improved antigen uptake of a glycopeptide sequence containing a CD8(+) T cell epitope could be achieved by delivering it on a liposome surface decorated with an immune complex-targeting ligand, an l-Rhamnose (Rha) epitope. We synthesized a 20-amino-acid glycopeptide TSAPDT(GalNAc)RPAPGSTAPPAHGV from the variable number tandem repeat region of the tumor marker MUC1 containing an N-terminal azido moiety and a tumor-associated α-N-acetyl galactosamine (GalNAc) at the immunogenic DTR motif. The MUC1 antigen was attached to Pam3Cys, a Toll-like receptor-2 ligand via copper(I)-catalyzed azido-alkyne cycloaddition (CuAAc) chemistry. The Rha-decorated liposomal Pam3Cys-MUC1-Tn 4 vaccine was evaluated in groups of C57BL/6 mice. Some groups were previously immunized to generate anti-Rha antibodies. Anti-Rha antibody expressing mice that received the Rha liposomal vaccine showed higher cellular immunogenicity compared to the control group while maintaining a strong humoral response.
Collapse
Affiliation(s)
- Partha Karmakar
- Department of Chemistry and Biochemistry, The University of Toledo, 2801 W. Bancroft Street, Toledo, OH 43606, United States
| | - Kyunghee Lee
- Department of Medicinal and Biological Chemistry, The University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States
| | - Sourav Sarkar
- Department of Chemistry and Biochemistry, The University of Toledo, 2801 W. Bancroft Street, Toledo, OH 43606, United States
| | - Katherine A. Wall
- Department of Medicinal and Biological Chemistry, The University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States
| | - Steven J. Sucheck
- Department of Chemistry and Biochemistry, The University of Toledo, 2801 W. Bancroft Street, Toledo, OH 43606, United States
| |
Collapse
|
22
|
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. BIOMED RESEARCH INTERNATIONAL 2015; 2015:490531. [PMID: 26509158 PMCID: PMC4609776 DOI: 10.1155/2015/490531] [Citation(s) in RCA: 139] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 05/28/2015] [Accepted: 05/31/2015] [Indexed: 12/13/2022]
Abstract
Cancer is the second most common cause of death in developed countries with approximately 14 million newly diagnosed individuals and over 6 million cancer-related deaths in 2012. Many cancers are discovered at a more advanced stage but better survival rates are correlated with earlier detection. Current clinically approved cancer biomarkers are most effective when applied to patients with widespread cancer. Single biomarkers with satisfactory sensitivity and specificity have not been identified for the most common cancers and some biomarkers are ineffective for the detection of early stage cancers. Thus, novel biomarkers with better diagnostic and prognostic performance are required. Aberrant protein glycosylation is well known hallmark of cancer and represents a promising source of potential biomarkers. Glycoproteins enter circulation from tissues or blood cells through active secretion or leakage and patient serum is an attractive option as a source for biomarkers from a clinical and diagnostic perspective. A plethora of technical approaches have been developed to address the challenges of glycosylation structure detection and determination. This review summarises currently utilised glycoprotein biomarkers and novel glycosylation-based biomarkers from the serum glycoproteome under investigation as cancer diagnostics and for monitoring and prognostics and includes details of recent high throughput and other emerging glycoanalytical techniques.
Collapse
|
23
|
Chugh S, Gnanapragassam VS, Jain M, Rachagani S, Ponnusamy MP, Batra SK. Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets. Biochim Biophys Acta Rev Cancer 2015; 1856:211-25. [PMID: 26318196 DOI: 10.1016/j.bbcan.2015.08.003] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Revised: 08/15/2015] [Accepted: 08/25/2015] [Indexed: 12/13/2022]
Abstract
Mucins are large glycoproteins expressed on the epithelia that provide a protective barrier against harsh insults from toxins and pathogenic microbes. These glycoproteins are classified primarily as being secreted and membrane-bound; both forms are involved in pathophysiological functions including inflammation and cancer. The high molecular weight of mucins is attributed to their large polypeptide backbone that is extensively covered by glycan moieties that modulate the function of mucins and, hence, play an important role in physiological functions. Deregulation of glycosylation machinery during malignant transformation results in altered mucin glycosylation. This review describes the functional implications and pathobiological significance of altered mucin glycosylation in cancer. Further, this review delineates various factors such as glycosyltransferases and tumor microenvironment that contribute to dysregulation of mucin glycosylation during cancer. Finally, this review discusses the scope of mucin glycan epitopes as potential diagnostic and therapeutic targets.
Collapse
Affiliation(s)
- Seema Chugh
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
| | - Vinayaga S Gnanapragassam
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
| | - Maneesh Jain
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA; Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
| | - Satyanarayana Rachagani
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
| | - Moorthy P Ponnusamy
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA; Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
| | - Surinder K Batra
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA; Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA.
| |
Collapse
|
24
|
Sungsuwan S, Yin Z, Huang X. Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines. ACS APPLIED MATERIALS & INTERFACES 2015; 7. [PMID: 26200668 PMCID: PMC4724168 DOI: 10.1021/acsami.5b05497] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Although iron oxide magnetic nanoparticles (NPs) have been widely utilized in molecular imaging and drug delivery studies, they have not been evaluated as carriers for glycoconjugate-based anticancer vaccines. Tumor-associated carbohydrate antigens (TACAs) are attractive targets for the development of anticancer vaccines. Due to the weak immunogenicity of these antigens, it is highly challenging to elicit strong anti-TACA immune responses. With their high biocompatibilities and large surface areas, magnetic NPs were synthesized for TACA delivery. The magnetic NPs were coated with phospholipid-functionalized TACA glycopeptides through hydrophobic-hydrophobic interactions without the need for any covalent linkages. Multiple copies of glycopeptides were presented on NPs, potentially leading to enhanced interactions with antibody-secreting B cells through multivalent binding. Mice immunized with the NPs generated strong antibody responses, and the glycopeptide structures important for high antibody titers were identified. The antibodies produced were capable of recognizing both mouse and human tumor cells expressing the glycopeptide, resulting in tumor cell death through complement-mediated cytotoxicities. These results demonstrate that magnetic NPs can be a new and simple platform for multivalently displaying TACA and boosting anti-TACA immune responses without the need for a typical protein carrier.
Collapse
|
25
|
Buba AE, Löwe H, Kunz H. Fluorenylmethoxycarbonyl-ProtectedO-Glycosyl-N-methyl Amino Acids: Building Blocks for the Synthesis of Conformationally Tuned Glycopeptide Antigens. European J Org Chem 2015. [DOI: 10.1002/ejoc.201500929] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
26
|
Palitzsch B, Glaffig M, Kunz H. Mucin Glycopeptide-Protein Conjugates - Promising Antitumor Vaccine Candidates. Isr J Chem 2015. [DOI: 10.1002/ijch.201400131] [Citation(s) in RCA: 188] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
27
|
Johannes M, Reindl M, Gerlitzki B, Schmitt E, Hoffmann-Röder A. Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope. Beilstein J Org Chem 2015; 11:155-161. [PMID: 25670999 PMCID: PMC4311645 DOI: 10.3762/bjoc.11.15] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 01/02/2015] [Indexed: 02/03/2023] Open
Abstract
The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4’F-TF-MUC1-TTox conjugate resulted in strong immune responses overriding the natural tolerance against MUC1 and producing selective IgG antibodies that are cross-reactive with native MUC1 epitopes on MCF-7 human cancer cells.
Collapse
Affiliation(s)
- Manuel Johannes
- Department of Chemistry and Center of Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians University, Butenandtstraße 5-13, D-81377 Munich, Germany
| | - Maximilian Reindl
- Department of Chemistry and Center of Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians University, Butenandtstraße 5-13, D-81377 Munich, Germany
| | - Bastian Gerlitzki
- Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstraße 1, Geb. 708, D-55101 Mainz, Germany
| | - Edgar Schmitt
- Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstraße 1, Geb. 708, D-55101 Mainz, Germany
| | - Anja Hoffmann-Röder
- Department of Chemistry and Center of Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians University, Butenandtstraße 5-13, D-81377 Munich, Germany
| |
Collapse
|
28
|
Huo CX, Zheng XJ, Xiao A, Liu CC, Sun S, Lv Z, Ye XS. Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates. Org Biomol Chem 2015; 13:3677-90. [DOI: 10.1039/c4ob02424a] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
N-Modified S-linked STn glycoconjugates significantly stimulated the production of IgG antibodies capable of recognizing the naturally occurring STn antigen.
Collapse
Affiliation(s)
- Chang-Xin Huo
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Xiu-Jing Zheng
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - An Xiao
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Chang-Cheng Liu
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Shuang Sun
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Zhuo Lv
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Xin-Shan Ye
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| |
Collapse
|
29
|
Zheng XJ, Yang F, Zheng M, Huo CX, Zhang Y, Ye XS. Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen. Org Biomol Chem 2015; 13:6399-406. [DOI: 10.1039/c5ob00405e] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
N-modified GM3 glycoconjugates improved the efficiency of the vaccination without the combination of metabolic oligosaccharide engineering technology.
Collapse
Affiliation(s)
- Xiu-Jing Zheng
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Fan Yang
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Mingwei Zheng
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Chang-Xin Huo
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| | - Ye Zhang
- School of Basic Medical Sciences
- Peking University
- Beijing 100191
- China
| | - Xin-Shan Ye
- State Key Laboratory of Natural and Biomimetic Drugs
- School of Pharmaceutical Sciences
- and Center for Molecular and Translational Medicine
- Peking University
- Beijing 100191
| |
Collapse
|
30
|
Halim A, Westerlind U, Pett C, Schorlemer M, Rüetschi U, Brinkmalm G, Sihlbom C, Lengqvist J, Larson G, Nilsson J. Assignment of saccharide identities through analysis of oxonium ion fragmentation profiles in LC-MS/MS of glycopeptides. J Proteome Res 2014; 13:6024-32. [PMID: 25358049 DOI: 10.1021/pr500898r] [Citation(s) in RCA: 105] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Protein glycosylation plays critical roles in the regulation of diverse biological processes, and determination of glycan structure-function relationships is important to better understand these events. However, characterization of glycan and glycopeptide structural isomers remains challenging and often relies on biosynthetic pathways being conserved. In glycoproteomic analysis with liquid chromatography-tandem mass spectrometry (LC-MS/MS) using collision-induced dissociation (CID), saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues are prominent. Through analysis of beam-type CID spectra and ion trap CID spectra of synthetic and natively derived N- and O-glycopeptides, we found that the fragmentation patterns of oxonium ions characteristically differ between glycopeptides terminally substituted with GalNAcα1-O-, GlcNAcβ1-O-, Galβ3GalNAcα1-O-, Galβ4GlcNAcβ-O-, and Galβ3GlcNAcβ-O- structures. The difference in the oxonium ion fragmentation profiles of such glycopeptides may thus be used to distinguish among these glycan structures and could be of importance in LC-MS/MS-based glycoproteomic studies.
Collapse
Affiliation(s)
- Adnan Halim
- Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, ‡Department of Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg , SE-41345 Gothenburg, Sweden
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Gao Y, Sun ZY, Huang ZH, Chen PG, Chen YX, Zhao YF, Li YM. Covalent bond or noncovalent bond: a supramolecular strategy for the construction of chemically synthesized vaccines. Chemistry 2014; 20:13541-6. [PMID: 25155367 DOI: 10.1002/chem.201404013] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Indexed: 01/07/2023]
Abstract
A novel noncovalent strategy to construct chemically synthesized vaccines has been designed to trigger a robust immune response and to dramatically improve the efficiency of vaccine preparation. Glycosylated MUC1 tripartite vaccines were constructed through host-guest interactions with cucurbit[8]uril. These vaccines elicited high levels of IgG antibodies that were recognized by transformed cells and induced the secretion of cytokines. The antisera also mediated complement-dependent cytotoxicity. This noncovalent strategy with good suitability, scalability, and feasibility can be applied as a universal strategy for the construction of chemically synthesized vaccines.
Collapse
Affiliation(s)
- Yue Gao
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University (P.R. China)
| | | | | | | | | | | | | |
Collapse
|
32
|
Ishiwata A, Kaeothip S, Takeda Y, Ito Y. Synthesis of the Highly Glycosylated Hydrophilic Motif of Extensins. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201404904] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
33
|
Ishiwata A, Kaeothip S, Takeda Y, Ito Y. Synthesis of the Highly Glycosylated Hydrophilic Motif of Extensins. Angew Chem Int Ed Engl 2014; 53:9812-6. [DOI: 10.1002/anie.201404904] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Indexed: 01/08/2023]
|
34
|
Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM. Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification. Vaccines (Basel) 2014; 2:549-62. [PMID: 26344745 PMCID: PMC4494217 DOI: 10.3390/vaccines2030549] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 05/30/2014] [Accepted: 06/04/2014] [Indexed: 12/29/2022] Open
Abstract
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.
Collapse
Affiliation(s)
- Zhi-Hua Huang
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| | - Zhan-Yi Sun
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| | - Yue Gao
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| | - Pu-Guang Chen
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| | - Yan-Fang Liu
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| | - Yong-Xiang Chen
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| | - Yan-Mei Li
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China.
| |
Collapse
|
35
|
Campo VL, Riul TB, Carvalho I, Baruffi MD. Antibodies against mucin-based glycopeptides affect Trypanosoma cruzi cell invasion and tumor cell viability. Chembiochem 2014; 15:1495-507. [PMID: 24920542 DOI: 10.1002/cbic.201400069] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Indexed: 01/13/2023]
Abstract
This study describes the synthesis of glycopeptides NHAc[βGal]-(Thr)2 -[αGalNAc]-(Thr)2 -[αGlcNAc]-(Thr)2 Gly-OVA (1-OVA) and NHAc[βGal-αGalNAc]-(Thr)3 -[αLacNAc]-(Thr)3 -Gly-OVA (2-OVA) as mimetics of both T. cruzi and tumor mucin glycoproteins. These glycopeptides were obtained by solid-phase synthesis, which involved the prior preparation of the protected glycosyl amino acids αGlcNAc-ThrOH (3), αGalNAc-ThrOH (4), βGal-ThrOH (5), αLacNAc-ThrOH (6), and βGal-αGalNAc-ThrOH (7) through glycosylation reactions. Immunizations of mice with glycopeptides 1-OVA and 2-OVA induced high antibody titers (1:16 000), as verified by ELISA tests, whereas flow cytometry assays showed the capacity of the obtained anti-glycopeptides 1-OVA and 2-OVA antibodies to recognize both T. cruzi and MCF-7 tumor cells. In addition, antisera induced by glycopeptides 1-OVA and 2-OVA were also able to inhibit T. cruzi fibroblast cell invasion (70 %) and to induce antibody-mediated cellular cytotoxicity (ADCC) against MCF-7 cells, with 50 % reduction of cell viability.
Collapse
Affiliation(s)
- Vanessa L Campo
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP, Av. Café S/N, CEP 14040-903, Ribeirão Preto, SP (Brazil)
| | | | | | | |
Collapse
|
36
|
Yu J, Westerlind U. Synthesis of a glycopeptide vaccine conjugate for induction of antibodies recognizing O-mannosyl glycopeptides. Chembiochem 2014; 15:939-45. [PMID: 24753400 DOI: 10.1002/cbic.201300537] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 01/30/2014] [Indexed: 01/30/2023]
Abstract
In spite of the clear importance of protein O-mannosylation in brain glycobiology, tools are lacking for specific detection, enrichment, and identification of proteins containing these modifycations. We envisioned inducing antibodies that specifically recognize O-mannose glycans on proteins and peptides. With this in mind, we prepared a glycopeptide vaccine construct containing the N-acetyllactosamine-extended mannose motif Galβ1-4GlcNAcβ1-2ManαThr, found as a common core structure on almost all mammalian O-mannosyl glycoproteins identified. O-mannose glycosylated amino acid building blocks and the corresponding glycopeptides were prepared by chemical synthesis and then conjugated to an immune carrier protein. After administration of the synthetic vaccine into rabbits, strong immune responses were obtained. Further evaluation by ELISA neutralization experiments and glycopeptide microarrays showed that the induced antibodies were highly specific to the glycopeptide antigen.
Collapse
Affiliation(s)
- Jin Yu
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227 Dortmund (Germany)
| | | |
Collapse
|
37
|
Sunasee R, Adokoh CK, Darkwa J, Narain R. Therapeutic potential of carbohydrate-based polymeric and nanoparticle systems. Expert Opin Drug Deliv 2014; 11:867-84. [DOI: 10.1517/17425247.2014.902048] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
38
|
Cai H, Sun ZY, Chen MS, Zhao YF, Kunz H, Li YM. Synthetic Multivalent Glycopeptide-Lipopeptide Antitumor Vaccines: Impact of the Cluster Effect on the Killing of Tumor Cells. Angew Chem Int Ed Engl 2014; 53:1699-703. [DOI: 10.1002/anie.201308875] [Citation(s) in RCA: 103] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Indexed: 01/04/2023]
|
39
|
Cai H, Sun ZY, Chen MS, Zhao YF, Kunz H, Li YM. Multivalente synthetische Glycopeptid-Lipopeptid-Antitumorvakzine: Auswirkung des Cluster-Effekts auf das Abtöten von Tumorzellen. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201308875] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
Abstract
MECA-79 antigen is a sulfated mucin type core-1 extended O-glycan which is a potential anti-inflammatory agent. Herein we report a total synthesis of MECA-79 via a convergent [2 + 2] glycosylation routethrough the intermediacy of Tn and TF antigens.
Collapse
Affiliation(s)
| | - Madhu Emmadi
- Department of Chemistry
- Indian Institute of Technology-Bombay
- Mumbai, India
| | - Suvarn S. Kulkarni
- Department of Chemistry
- Indian Institute of Technology-Bombay
- Mumbai, India
| |
Collapse
|
41
|
Wurm FR, Klok HA. Be squared: expanding the horizon of squaric acid-mediated conjugations. Chem Soc Rev 2013; 42:8220-36. [PMID: 23873344 DOI: 10.1039/c3cs60153f] [Citation(s) in RCA: 103] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Squaric acid diesters can be applied as reagents to couple two amino-functional compounds. Consecutive coupling of two amines allows the synthesis of asymmetric squaric acid bisamides with either low molecular weight compounds but also biomolecules or polymers. The key feature of the squaric acid diester mediated coupling is the reduced reactivity of the resulting ester-amide after the first amidation step of the diester. This allows the sequential amidation and generation of asymmetric squaramides with high selectivity and in high yields. This article gives an overview of the well-established squaric acid diester mediated coupling reactions for glycoconjugates and presents recent advances that aim to expand this very versatile reaction protocol to the modification of peptides and proteins.
Collapse
Affiliation(s)
- Frederik R Wurm
- Max Planck Institut für Polymerforschung, Ackermannweg 10, 55128 Mainz, Germany.
| | | |
Collapse
|
42
|
Parry A, Clemson NA, Ellis J, Bernhard SSR, Davis BG, Cameron NR. 'Multicopy multivalent' glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines. J Am Chem Soc 2013; 135:9362-5. [PMID: 23763610 PMCID: PMC3928990 DOI: 10.1021/ja4046857] [Citation(s) in RCA: 179] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2013] [Indexed: 01/18/2023]
Abstract
Mucin-related carbohydrates are overexpressed on the surface of cancer cells, providing a disease-specific target for cancer immunotherapy. Here, we describe the design and construction of peptide-free multivalent glycosylated nanoscale constructs as potential synthetic cancer vaccines that generate significant titers of antibodies selective for aberrant mucin glycans. A polymerizable version of the Tn-antigen glycan was prepared and converted into well-defined glycopolymers by Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization. The polymers were then conjugated to gold nanoparticles, yielding 'multicopy-multivalent' nanoscale glycoconjugates. Immunological studies indicated that these nanomaterials generated strong and long-lasting production of antibodies that are selective to the Tn-antigen glycan and cross-reactive toward mucin proteins displaying Tn. The results demonstrate proof-of-concept of a simple and modular approach toward synthetic anticancer vaccines based on multivalent glycosylated nanomaterials without the need for a typical vaccine protein component.
Collapse
Affiliation(s)
- Alison
L. Parry
- Department of Chemistry and
Biophysical Sciences Institute, Durham University, South Road, Durham, DH1 3LE, U.K
- Department of Chemistry, University of Oxford, Chemistry Research Laboratory,
12 Mansfield Road, Oxford, OX1 3TA, U.K
| | - Natasha A. Clemson
- Department of Chemistry and
Biophysical Sciences Institute, Durham University, South Road, Durham, DH1 3LE, U.K
| | - James Ellis
- Department of Chemistry and
Biophysical Sciences Institute, Durham University, South Road, Durham, DH1 3LE, U.K
| | - Stefan S. R. Bernhard
- Department of Chemistry and
Biophysical Sciences Institute, Durham University, South Road, Durham, DH1 3LE, U.K
| | - Benjamin G. Davis
- Department of Chemistry, University of Oxford, Chemistry Research Laboratory,
12 Mansfield Road, Oxford, OX1 3TA, U.K
| | - Neil R. Cameron
- Department of Chemistry and
Biophysical Sciences Institute, Durham University, South Road, Durham, DH1 3LE, U.K
| |
Collapse
|
43
|
Cai H, Chen MS, Sun ZY, Zhao YF, Kunz H, Li YM. MUC1-Glycopeptidkonjugate mit T-Zellepitopen von Tetanus-Toxoid als vollsynthetische Antitumor-Vakzine mit Eigenverstärkungseffekt. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201300390] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
44
|
Cai H, Chen MS, Sun ZY, Zhao YF, Kunz H, Li YM. Self-Adjuvanting Synthetic Antitumor Vaccines from MUC1 Glycopeptides Conjugated to T-Cell Epitopes from Tetanus Toxoid. Angew Chem Int Ed Engl 2013; 52:6106-10. [DOI: 10.1002/anie.201300390] [Citation(s) in RCA: 99] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2013] [Revised: 02/15/2013] [Indexed: 12/15/2022]
|
45
|
One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid. Bioorg Med Chem 2013; 21:4778-85. [PMID: 23535562 DOI: 10.1016/j.bmc.2013.02.040] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Revised: 02/17/2013] [Accepted: 02/26/2013] [Indexed: 02/01/2023]
Abstract
A series of STn-MUC1 and ST-MUC1 glycopeptides containing naturally occurring and non-natural sialic acids have been chemoenzymatically synthesized from Tn-MUC1 glycopeptide using one-pot multienzyme (OPME) approaches. In situ generation of the sialyltransferase donor cytidine 5'-monophosphate-sialic acid (CMP-Sia) using a CMP-sialic acid synthetase in the presence of an extra amount of cytidine 5'-triphosphate (CTP) and removal of CMP from the reaction mixture by flash C18 cartridge purification allow the complete consumption of Tn-MUC1 glycopeptide for quantitative synthesis of STn-MUC1. A Campylobacter jejuni β1-3GalT (CjCgtBΔ30-His6) mutant has been found to catalyze the transfer of one or more galactose residues to Tn-MUC1 for the synthesis of T-MUC1 and galactosylated T-MUC1. Sialylation of T-MUC1 using Pasteurella multocida α2-3-sialyltransferase 3 (PmST3) with Neisseria meningitidis CMP-sialic acid synthetase (NmCSS) and Escherichia coli sialic acid aldolase in one pot produced ST-MUC1 efficiently. These glycopeptides are potential cancer vaccine candidates.
Collapse
|
46
|
Gaidzik N, Westerlind U, Kunz H. The development of synthetic antitumour vaccines from mucin glycopeptide antigens. Chem Soc Rev 2013; 42:4421-42. [PMID: 23440054 DOI: 10.1039/c3cs35470a] [Citation(s) in RCA: 344] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Based on important cell-biological and biochemical results concerning the structural difference between membrane glycoproteins of normal epithelial cells and epithelial tumour cells, tumour-associated glycopeptide antigens have been chemically synthesised and structurally confirmed. Glycopeptide structures of the tandem repeat sequence of mucin MUC1 of epithelial tumour cells constitute the most promising tumour-associated antigens. In order to generate a sufficient immunogenicity of these endogenous structures, usually tolerated by the immune system, these synthetic glycopeptide antigens were conjugated to immune stimulating components: in fully synthetic two-component vaccines either with T-cell peptide epitopes or with Toll-like receptor2 lipopeptide ligands or in three-component vaccines with both these stimulants. Alternatively, the synthetic glycopeptide antigens were coupled to immune stimulating carrier proteins. In particular, MUC1 glycopeptide conjugates with Tetanus toxoid proved to be efficient vaccines inducing very strong immune responses in mice. The antibodies elicited with the fully synthetic vaccines showed selective recognition of the tumour-associated glycopeptides as was shown by neutralisation and micro-array binding experiments. After booster immunisations, most of the immune responses showed the installation of an immunological memory. Immunisation with fully synthetic three-component vaccines induced immune reactions with therapeutic effects in terms of reduction of the tumour burden in mice or in killing of tumour cells in culture, while MUC1 glycopeptide-Tetanus toxoid vaccines elicited antibodies in mice which recognised tumour cells in human tumour tissues. The results achieved so far are considered to be promising for the development of an active immunisation against tumours.
Collapse
Affiliation(s)
- Nikola Gaidzik
- Johannes Gutenberg-Universität Mainz, Institut für Organische Chemiem, Duesbergweg 10-14, D-55128 Mainz, Germany
| | | | | |
Collapse
|
47
|
Al Sheikha D, Wilkinson BL, Santhakumar G, Thaysen-Andersen M, Payne RJ. Synthesis of homogeneous MUC1 oligomers via a bi-directional ligation strategy. Org Biomol Chem 2013; 11:6090-6. [DOI: 10.1039/c3ob41363b] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
48
|
Cai H, Sun ZY, Huang ZH, Shi L, Zhao YF, Kunz H, Li YM. Fully Synthetic Self-Adjuvanting Thioether-Conjugated GlycopeptideLipopeptide Antitumor Vaccines for the Induction of Complement-Dependent Cytotoxicity against Tumor Cells. Chemistry 2012; 19:1962-70. [DOI: 10.1002/chem.201203709] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Indexed: 01/24/2023]
|
49
|
Dingels C, Wurm F, Wagner M, Klok HA, Frey H. Squaric Acid Mediated Chemoselective PEGylation of Proteins: Reactivity of Single-Step-Activated α-Amino Poly(ethylene glycol)s. Chemistry 2012; 18:16828-35. [DOI: 10.1002/chem.201200182] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2012] [Revised: 08/13/2012] [Indexed: 02/05/2023]
|
50
|
Wilkinson BL, Day S, Chapman R, Perrier S, Apostolopoulos V, Payne RJ. Synthesis and Immunological Evaluation of Self-Assembling and Self-Adjuvanting Tricomponent Glycopeptide Cancer-Vaccine Candidates. Chemistry 2012; 18:16540-8. [DOI: 10.1002/chem.201202629] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Revised: 09/04/2012] [Indexed: 12/31/2022]
|